Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Description Retatrutide 10mg Triple Agonist (GLP-1/GIP/Glucagon) Research Peptide Retatrutide is a synthetic triple receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneously, studied as a next-generation metabolic research compound
.png.jpg)
Follow-up appointments are scheduled to ensure steady progress, and we create a maintenance plan that includes relapse prevention tools for travel and busy seasons
You must be at least 18 years old, enrolled in a Medicare Part D plan, and prescribed the medication specifically to reduce excess body weight in combination with ongoing lifestyle modifications, including structured nutrition and physical activity consistent with the FDA-approved label
One phase 3 clinical trial found that survodutide led to an average 12% to 18.7% body weight reduction , depending on dose, in adults with obesity and without diabetes after 76 weeks compared to 5% in the placebo group
